Park Square is pleased to announce the placement of Charles Allerson, Ph.D., as Chief Technology Officer at Switch Therapeutics.
Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat diseases utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).
unknownx500
More posts by Park Square Executive Search
Recent posts from Park Square Executive Search
